Sümeyye DEMİRBAY, Neslihan CANSEL, Hatice Birgül CUMURCU, Zehra ALGAN

Use of Vanoxerine Consta In Cocaine Addiction: A Case Report

Cocaine abuse is a serious health problem in many regions of the world, however, there are no proven effective drugs for the treatment of cocaine addiction. In this presentation,diagnosis, treatment and monitoring processes of a 33-year-old male patient, using vanoxerine constants in the treatment of cocaine addiction, will be shared. In the story taken, it was learned that the patient started to use cocaine 7-8 months ago.After the patient was applied a intramuscular treatment, 394,2 mg of vanoxerine consta, three times with three months intervals, it was observed that withdrawal symptoms and cocaine desire decreased.In addition, one-year follow-up of the patient revealed that his well-being continued and the urine substance panels were negative.Vanoxerin limits cocaine-induced increase in extracellular dopamine by competing with cocaine in the dopamine transporter region.Cocaine abuse is a harmful habit spreading to the world, causing socioeconomic problems.

Keywords:

addiction, cocaine, vanoxerine,

PDF

___

Andersen, P. H. (1989). The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action.European Journal of Pharmacology, 166, 493-509.
Andersen, P. H. (1989). The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. European journal of pharmacology, 166(3), 493-504
Castells, X., Casas, M., Pérez‐Mañá, C., Roncero, C., Vidal, X., & Capella, D. (2010). Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews, (2).
Fensbo, C., Montgomery, S. A., Andersen, J., Hallstrom, C., Schonbeck, G., Zwaan, M., M0oler Nielsen, E. M., Olafsson, K., Ingwersen, S. H. & Skrumsager, B. K. (1990). GBR 12909: A dose response relationship of the selective dopamine uptake inhibitor in major depression. XVIIth Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto. Abstract 0-11-9-3.
Glowa, J.R., Wojnicki, F.H.E., Matecka, D., Rice, K.C., Rothman, R.B. (1995b) Effects of dopamine reuptake inhibitors on food and cocaine maintained responding II: comparison with other drugs and repeated administration .Experimental and Clinical Psychopharmacology 3:232–239.
Hanzlick, R., Gowitt, G.T., (1991). Cocaine metabolite detection in homicide victims. The Journal of the American Medical Association 265:760–761.
Holman, R.B. (1994). Biological effects of central nervous system stimulants. Addiction, 89(11), 1435-1441.
Hyman, S.E. (1996) Addiction to cocaine and amphetamine. Neuron, 16(5), 901-904.
Kalivas, P.W.; Duffy, P. (1990) Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse, 5(1), 48-58.
Koob, G.F. Nestler, E.J. (1997). The neurobiology of drug addiction. The Journal of Neuropsychiatry and Clinical Neurosciences, 9(3), 482-497.
Luoh, H.F. Kuo, T.B. Chan, S.H. Pan, W.H. (1994). Power spectral analysis of electroencephalographic desynchronization induced by cocaine in rats: correlation with microdialysis evaluation of dopaminergic neurotransmission at the medial prefrontal cortex. Synapse, 16(1), 29-35.
Matsumoto, N., Khrestian, C. M., Ryu, K., Lacerda, A. E., Brown, A. M., & Waldo, A. L. (2010). Vanoxerine, a new drug for terminating atrial fibrillation and flutter. Journal of cardiovascular electrophysiology, 21(3), 311-319.
Rothman, R.B., Mele, A., Reid, A.A., Akunne, H.C., Greig, N., Thurkauf, A. (1991). GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacology Biochemistry and Behavior, 40:387–397.
Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Gatley, S.J., Wong, C. (1999). Reinforcing effects of psychostimulants in humans areassociated with increases in brain dopamine and occupancyof D2 receptors.Journal of Pharmacology and Experimental Therapeutics 291:409–415.
Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., ... & Swanson, J. M. (2002). Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse, 43(3), 181-187.